Search
News & Events
Patients with antibiotic-resistant lung infections to receive promising phage therapy treatment as part of new trial led by The Kids Research Institute Australia Researcher Anthony KicicPatients with lung infections that are not responding to antibiotics will be treated with phage therapy as part of a translational trial program to be undertaken by world-recognised experts in this field.
News & Events
International trial shows that interferon could help reduce the spread of COVID-19Results of an innovative clinical trial led by Perth researchers have shown that the drug interferon could help reduce the spread of COVID-19 from a positive person to their household contacts, with the study helping to inform treatment options for a future pandemic.
News & Events
Research to see if AI can speed up therapy for people with antibiotic-resistant bacterial infectionsResearchers from the Wal-yan Respiratory Research Centre are aiming to combine artificial intelligence with natural, infection-fighting viruses to help save lives from an increasingly common medical emergency found in hospitals.
News & Events
The Wal-yan Respiratory Research Centre turns three!As the Wal-yan Respiratory Research Centre turns three, we celebrate our achievements, and say thank you to our amazing community.
News & Events
Great minds come together at Wal-yan Scientific RetreatWal-yan Respiratory Research Centre team members and special guests travelled to Wadjemup (Rottnest) on 27 and 28 October to spend an intensive two days together learning about, and providing input into, the broad range of research projects underway within the Centre.
Learn more about the supporters of the Wal-yan Respiratory Centre
Phage WA have a number of projects underway and these cover a broad range of phage research areas.
"Compassionate Use" treatments are novel treatments not widely available to everyone, but ones that holds great promise for potentially becoming a widely used treatment in the future.
Research
Pseudomonas aeruginosa Resistance to Bacteriophages and Its Prevention by Strategic Therapeutic Cocktail FormulationAntimicrobial resistance poses a significant threat to modern healthcare as it limits treatment options for bacterial infections, particularly impacting those with chronic conditions such as cystic fibrosis (CF). Viscous mucus accumulation in the lungs of individuals genetically predisposed to CF leads to recurrent bacterial infections, necessitating prolonged antimicrobial chemotherapy. Pseudomonas aeruginosa infections are the predominant driver of CF lung disease, and airway isolates are frequently resistant to multiple antimicrobials.
Research
The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trialStructural lung disease and neutrophil-dominated airway inflammation is present from 3 months of age in children diagnosed with cystic fibrosis after newborn screening. We hypothesised that azithromycin, given three times weekly to infants with cystic fibrosis from diagnosis until age 36 months, would reduce the extent of structural lung disease as captured on chest CT scans.